Real-World Effectiveness and Safety of Ribociclib Plus Aromatase Inhibitors in Patients with HR+/HER2- Metastatic Breast Cancer: A Multicenter Experience from Vietnam.

Asian Pac J Cancer Prev · 2025 · PMC12948174 · PMID 41312949

Europe PMC DOI

hedged sentences

0.0780

closest p · 1.6× alpha

0.0780

boldest claim

The sentences

did not reach statistical significancep = 0.078so close (0.05 < p ≤ 0.1)

16.1 months), though the difference did not reach statistical significance (p = 0.078).

also in 111,027 other papers

a clear trendno p-value reported

However, their study demonstrated a clear trend toward decreased efficacy with later lines of treatment, which was not evident in our cohort when first-line versus subsequent-line therapy was compared [ 23 ].

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.